An American Heart Association study has found that daily marijuana use is linked to a significantly higher risk of heart attack and stroke. And the increased danger exists whether users smoke, vape or eat their cannabis products.
Los Angeles, California – What once looked like the next great American industry now finds itself stalled at the intersection of sluggish regulation, collapsing valuations, and brutal market realities. The legal cannabis sector, once projected to generate billions in revenue and revolutionize everything from medicine to tax bases, is showing signs of strain — and in some corners, outright collapse.
California, where legalization was once a model for national reform, has become a cautionary tale. Despite legal status and cultural acceptance, the state’s legal cannabis market continues to suffer from overregulation, high taxes, and competition from an entrenched illegal market. And California’s story is not unique. Across the country, a patchwork of state laws has led to logistical headaches and stunted national growth.
Back in 2021, industry optimism peaked. Four of North America’s largest cannabis companies — Curaleaf, Green Thumb Industries, Tilray Brands, and Trulieve — were collectively valued at $37 billion. At the time, the political winds seemed favorable: President Joe Biden was in office, new states like New York and Virginia were legalizing recreational use, and there was talk of federal reform.
But nearly three years later, the high has worn off. Those same four companies are now worth just $4 billion combined. Their average valuation has plummeted, forward revenue projections have flattened, and losses are expected to continue into next year. The massive drop is partly due to a fundamental miscalculation: the assumption that legalization would spread quickly across the U.S. and abroad.
Instead, the movement has stalled. Not a single U.S. state has legalized recreational cannabis in 2023 or 2024. Meanwhile, efforts to reschedule cannabis at the federal level — potentially easing tax burdens and improving access to banking services — remain in limbo. Overseas, momentum is equally mixed. Thailand, once seen as a trailblazer in Southeast Asia, recently reversed course and banned recreational use. Even in Germany, where cannabis was recently decriminalized, progress has been halting and cautious.
Another issue is simple economics. Legalization led to an oversupply of marijuana, driving down prices. In New York, the number of dispensaries ballooned to more than 300 in just three years. Retail prices across the U.S. have dropped 32% during that same period, creating a race to the bottom for producers and sellers. Add in restrictive local regulations and high taxes — sometimes exceeding 30% in states like California — and the legal market begins to look less like a business opportunity and more like a regulatory trap.
Yet even amid the downturn, some see glimmers of hope. The nascent German market, expected to grow 14% annually through 2030, has attracted interest from U.S. and Canadian firms eager for new territory. But at $37 million in total value last year, it remains a far cry from the industry’s grand ambitions.
For now, the cannabis industry finds itself in a kind of purgatory: too legal to be rebellious, too regulated to be profitable. The dreams may not be dead, but they’re certainly clouded — and the buzz that once surrounded Big Cannabis has all but dissipated.
